Disagree, case in point being the other company you hold. Mesoblast held multiple agreements with big pharma for a variety of indications prior to approval of paediatric SR-aGvHD.
Post P2 results/pre Phase 3 trials is when a lot of these agreements take place. The good news is that Cynata's P2 trial in adult HR-aGvHD is due to readout in about 9 months, with the 321 patient Phase 3 trial in knee osteoarthritis due to read out in about 12 months, too. There's two indications primed for a deal.
CYP Price at posting:
19.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)